Advances in Endovascular Therapy for Infrainguinal Peripheral Arterial Disease: Devices and Outcomes

Abstract

The management of infrainguinal peripheral arterial disease (PAD) has undergone a remarkable transformation over the past two decades, driven by rapid innovation in drug delivery systems, plaque-modifying technologies, intravascular imaging, and minimally invasive bypass alternatives. This review summarizes contemporary advances in endovascular therapy and highlights the clinical evidence supporting each major device category. Drug-coated balloons and drug-eluting stents remain foundational technologies in treating PAD. Paclitaxel-coated platforms have demonstrated durable reductions in target lesion revascularization in multiple randomized trials, while sirolimus-based devices have recently emerged as viable alternatives. The LIFE-BTK trial established the first everolimus-eluting scaffold with proven improvements in restenosis among patients with chronic limb-threatening ischemia. Equally transformative has been the evolution of lesion-preparation strategies. Atherectomy, scoring balloons, and intravascular lithotripsy (IVL) have improved vessel compliance, reduced recoil, and optimized drug uptake, particularly in heavily calcified lesions. Among these, IVL has gained rapid global adoption due to its safety profile and ability to modify deep calcium using low-pressure balloon inflation. The 355-nm laser and contemporary orbital atherectomy systems have expanded treatment options for complex, long, calcified, and below-the-knee lesions. Intravascular ultrasound (IVUS) consistently outperforms angiography in vessel sizing, dissection detection, and optimization of stent deployment. Multiple large registries and randomized trials have demonstrated significant improvements in patency, limb salvage, and clinical outcomes with IVUS-guided therapy. Finally, the fully percutaneous DETOUR bypass system offers a novel alternative for patients with long-segment femoropopliteal occlusions who are poor surgical candidates. This stent-based bypass technique has shown promising mid-term patency, high limb salvage rates, and low deep-vein thrombosis incidence. Collectively, these advances underscore the importance of individualized, multimodal endovascular therapy that aims to leave the least amount of metal behind while maintaining good long-term outcomes. Ongoing randomized trials and long-term data will continue to sharpen best practices and define the optimal role of each technology in treating complex PAD.

Keywords

endovascular procedure - peripheral arterial disease - superficial femoral artery disease - drug elution - vessel prepping - tibial disease - claudication

Publication History

Received: 13 January 2026

Accepted: 27 January 2026

Article published online:
17 February 2026

• References

• 1 Gornik HL, Aronow HD, Goodney PP. et al; Peer Review Committee Members. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation 2024; 149 (24) e1313-e1410
• 2 Chen X, Wang W, Dong S. et al. Trends of the burden, risk factors, and future projections of peripheral artery disease in the elderly. BMC Geriatr 2025; 25 (01) 589
• 3 Goodney PP, Beck AW, Nagle J, Welch HG, Zwolak RM. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg 2009; 50 (01) 54-60
• 4 Rowe VL, Lee W, Weaver FA, Etzioni D. Patterns of treatment for peripheral arterial disease in the United States: 1996-2005. J Vasc Surg 2009; 49 (04) 910-917
• 5 Criqui MH, Matsushita K, Aboyans V. et al; American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; and Stroke Council. Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association. Circulation 2021; 144 (09) e171-e191
• 6 Tarricone A, Ali Z, Rajamanickam A. et al. Histopathological evidence of adventitial or medial injury is a strong predictor of restenosis during directional atherectomy for peripheral artery disease. J Endovasc Ther 2015; 22 (05) 712-715
• 7 Li H, Rha S-W, Choi BG. et al. Impact of chronic outward force on arterial responses of proximal and distal of long superficial femoral artery stent. BMC Cardiovasc Disord 2021; 21 (01) 323
• 8 Lukacs RA, Weisshaar LI, Tornyos D, Komocsi A. Comparing endovascular approaches in lower extremity artery disease: insights from a network meta-analysis. J Clin Med 2024; 13 (04) 1024
• 9 Teleb M, Wardi M, Gosavi S, Said S, Mukherjee D. Paclitaxel-coated balloons: review of a promising interventional approach to preventing restenosis in femoropopliteal arteries. Int J Angiol 2016; 25 (02) 75-80
• 10 Teichgräber U, Ingwersen M, Platzer S. et al. Head-to-head comparison of sirolimus- versus paclitaxel-coated balloon angioplasty in the femoropopliteal artery: study protocol for the randomized controlled SIRONA trial. Trials 2021; 22 (01) 665
• 11 Varcoe RL, DeRubertis BG, Kolluri R. et al; LIFE-BTK Investigators. Drug-eluting resorbable scaffold versus angioplasty for infrapopliteal artery disease. N Engl J Med 2024; 390 (01) 9-19
• 12 Soga Y, Iida O, Saito S. et al. 3-year results following femoropopliteal lesion treatment with a novel sirolimus-eluting balloon. JACC Cardiovasc Interv 2025; 18 (21) 2629-2637
• 13 Katsanos K, Spiliopoulos S, Diamantopoulos A, Karnabatidis D, Sabharwal T, Siablis D. Systematic review of infrapopliteal drug-eluting stents: a meta-analysis of randomized controlled trials. Cardiovasc Intervent Radiol 2013; 36 (03) 645-658
• 14 Dake MD, Ansel GM, Jaff MR. et al; Zilver PTX Investigators. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation 2016; 133 (15) 1472-1483 , discussion 1483
• 15 Gray WA, Keirse K, Soga Y. et al; IMPERIAL investigators. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet 2018; 392 (10157): 1541-1551
• 16 Müller-Hülsbeck S, Benko A, Soga Y. et al. Two-year efficacy and safety results from the IMPERIAL randomized study of the eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent. Cardiovasc Intervent Radiol 2021; 44 (03) 368-375
• 17 Shibata T, Iba Y, Shingaki M. et al. Editor's choice - comparative analysis of three year results of two paclitaxel related stents for the management of femoropopliteal disease in a real world setting. Eur J Vasc Endovasc Surg 2025; 69 (06) 865-873
• 18 Sidiropoulou K, Tigkiropoulos K, Chatziathanasiou D. et al. 12 months outcomes of polymer-free amphilimus eluting stent nitides in patients with complex femoropopliteal arterial disease - a single center experience. Ann Vasc Surg 2026; 122: 564-571
• 19 Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2018; 7 (24) e011245
• 20 Zeller T, Dake MD, Tepe G. et al. IN.PACT SFA trial: long-term results of a randomized trial evaluating a paclitaxel-coated balloon for femoropopliteal disease. Circ Cardiovasc Interv 2019; 12 (06) e007702
• 21 Schneider PA, Laird JR, Tepe G. et al; IN.PACT SFA Trial Investigators. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial. Circ Cardiovasc Interv 2018; 11 (01) e005891
• 22 Steiner S, Schmidt A, Zeller T. et al. Twelve-month results from the first-in-human randomized trial of the Ranger paclitaxel-coated balloon for femoropopliteal disease (RANGER SFA). JACC Cardiovasc Interv 2018; 11 (10) 1105-1113
• 23 Krishnan P, Brodmann M, Holden A. et al. Stellarex drug-coated balloon for the treatment of femoropopliteal disease: 5-year outcomes from the ILLUMENATE pivotal randomized trial. Am J Cardiol 2024; 208: 77-85
• 24 Schröë H, Holden A, Goueffic Y. et al. Stellarex drug-coated balloon for treatment of femoropopliteal disease: 2-year outcomes of the ILLUMENATE European randomized clinical trial. Catheter Cardiovasc Interv 2018; 91 (03) 497-504 PMC
• 25 Stefano B, Tim S, Davide Voci. et al. Major adverse limb events in patients with femoro-popliteal and below-the-knee peripheral arterial disease treated with either sirolimus-coated balloon or standard uncoated balloon angioplasty: a structured protocol summary of the "SirPAD" randomized controlled trial. 2022; 23 (01) 334
• 26 Kamenskiy A, Poulson W, Sim S, Reilly A, Luo J, MacTaggart J. Prevalence of calcification in human femoropopliteal arteries and its association with demographics, risk factors, and arterial stiffness. Arterioscler Thromb Vasc Biol 2018; 38 (04) e48-e57
• 27 Fanelli F, Cannavale A, Gazzetti M. et al. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol 2014; 37 (04) 898-907
• 28 Shammas NW, Torey JT, Shammas WJ, Jones-Miller S, Shammas GA. Intravascular ultrasound assessment and correlation with angiographic findings demonstrating femoropopliteal arterial dissections post-atherectomy: results from the iDissection study. J Invasive Cardiol 2018; 30 (07) 240-244
• 29 Iida O, Takahara M, Soga Y. et al. Vessel diameter evaluated by intravascular ultrasound and angiography in femoropopliteal artery disease undergoing endovascular therapy. J Endovasc Ther 2022; 29 (03) 343-349
• 30 Shammas NW, Torey JT, Shammas WJ. Dissections in peripheral vascular interventions: a proposed classification using intravascular ultrasound. J Invasive Cardiol 2018; 30 (04) 145-146
• 31 Fereydooni A, Chandra V, Schneider PA, Giasolli R, Lichtenberg M, Stahlhoff S. Serration angioplasty is associated with less recoil in infrapopliteal arteries compared with plain balloon angioplasty. J Endovasc Ther 2025; 32 (05) 1600-1606
• 32 Lugenbiel I, Grebner M, Zhou Q. et al. Treatment of femoropopliteal lesions with the AngioSculpt scoring balloon - results from the Heidelberg PANTHER registry. Vasa 2018; 47 (01) 49-55
• 33 Scheinert D, Peeters P, Bosiers M, O'Sullivan G, Sultan S, Gershony G. Results of the multicenter first-in-man study of a novel scoring balloon catheter for the treatment of infra-popliteal peripheral arterial disease. Catheter Cardiovasc Interv 2007; 70 (07) 1034-1039
• 34 Giannopoulos S, Volteas P, Virvilis D. Specialty balloons for vessel preparation during infrainguinal endovascular revascularization procedures: a review of literature. Vasc Endovascular Surg 2023; 57 (06) 599-606
• 35 Shammas NW, Shammas WJ, Shammas GA, Jones-Miller S. Femoropopliteal arterial dissections following FLEX VP and balloon angioplasty versus balloon angioplasty alone: intravascular ultrasound assessment and correlation with angiographic findings. Cardiovasc Revasc Med 2022; 44: 62-66
• 36 Haraguchi T, Tsujimoto M, Otake R, Kashima Y, Sato K, Fujita T. Propensity score-matched analysis of six-month outcomes of paclitaxel-coated balloons combined with UltraScore balloons versus conventional scoring balloons for femoropopliteal lesions. Diagn Interv Radiol 2023; 29 (03) 535-541
• 37 Kim JM, Li S, Song Y, Yeh RW, Wadhera R, Secemsky EA. The shifting landscape of chronic limb-threatening ischemia revascularization toward ambulatory surgical centers and outpatient-based laboratories. JACC Cardiovasc Interv 2025; 18 (21) 2641-2652
• 38 Sansosti AA, Munoz J, Lazar AN. et al. Practice patterns in utilization of atherectomy and embolic protection devices in inpatient and outpatient treatment settings. J Vasc Surg 2024; 80 (06) 1806-1812.e4
• 39 Shammas NW, Shammas GA, Coiner D. et al. Percutaneous lower extremity arterial interventions using scoring balloon angioplasty vs conventional angioplasty: results of the CALCIUM 360° trial. J Endovasc Ther 2012; 19 (04) 480-488
• 40 Das TS, Shammas NW, Yoho JA. et al. Solid state, pulsed-wave 355 nm UV laser atherectomy debulking in the treatment of infrainguinal peripheral arterial disease: the pathfinder registry. Catheter Cardiovasc Interv 2024; 103 (06) 949-962
• 41 Shammas NW, Yates T, Sastry A. et al. Twelve-month outcomes of the prospective, multicenter, single-arm study of the 355-nm laser for treatment of below-the-knee arteries: final results of the Auryon BTK. J Endovasc Ther 2025;202516:15266028251352772
• 42 Shammas NW, Coiner D, Shammas GA, Dippel EJ, Christensen L, Jerin M. Percutaneous lower-extremity arterial interventions with primary balloon angioplasty versus Silverhawk atherectomy and adjunctive balloon angioplasty: randomized trial. J Vasc Interv Radiol 2011; 22 (09) 1223-1228
• 43 McKinsey JF, Zeller T, Rocha-Singh KJ, Jaff MR, Garcia LA. DEFINITIVE LE Investigators. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. JACC Cardiovasc Interv 2014; 7 (08) 923-933
• 44 Laird JR, Zeller T, Gray BH. et al; LACI Investigators. Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of the LACI multicenter trial. J Endovasc Ther 2006; 13 (01) 1-11
• 45 Kuczmik W, Oszkinis G, Kruszyna Ł. et al. Percutaneous photoacoustic debulking of infra-inguinal atherosclerotic disease- early European experience with a novel, solid-state, pulsed -wave, ultraviolet 355 nm laser. Lasers Med Sci 2025; 40 (01) 4
• 46 Auryon Atherectomy System with Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone (AMBITION BTK). (NCT06777901). Accessed December 21, 2025, at: https://clinicaltrials.gov/study/nct06777901
• 47 Dattilo R, Himmelstein SI, Cuff RF. The COMPLIANCE 360° trial: a randomized, prospective, multicenter, pilot study comparing acute and long-term results of orbital atherectomy to balloon angioplasty for calcified femoropopliteal disease. J Invasive Cardiol 2014; 26 (08) 355-360
• 48 Das T, Mustapha J, Indes J. et al. Technique optimization of orbital atherectomy in calcified peripheral lesions of the lower extremities: the CONFIRM series, a prospective multicenter registry. Catheter Cardiovasc Interv 2014; 83 (01) 115-122
• 49 Evaluation of the FreedomFlow Orbital Atherectomy System to Treat Peripheral Artery Disease (FASTII). Accessed November 28, 2025, at: https://clinicaltrials.gov/study/nct03635190?tab=results
• 50 Gray WA, Garcia LA, Amin A, Shammas NW. JET Registry Investigators. Jetstream atherectomy system treatment of femoropopliteal arteries: results of the post-market JET registry. Cardiovasc Revasc Med 2018; 19 (5 Pt A): 506-511
• 51 Shammas NW, Shammas GA, Banerjee S, Popma JJ, Mohammad A, Jerin M. JetStream rotational and aspiration atherectomy in treating in-stent restenosis of the femoropopliteal arteries: results of the JETSTREAM-ISR feasibility study. J Endovasc Ther 2016; 23 (02) 339-346
• 52 Shammas NW, Petruzzi N, Henao S. et al. JetStream atherectomy for the treatment of in-stent restenosis of the femoropopliteal segment: one-year results of the JET-ISR study. J Endovasc Ther 2021; 28 (01) 107-116
• 53 Shammas NW, Purushottam B, Shammas WJ. et al; JET-RANGER Investigators. Jetstream atherectomy followed by paclitaxel-coated balloons versus balloon angioplasty followed by paclitaxel-coated balloons: twelve-month exploratory results of the prospective randomized JET-RANGER study. Vasc Health Risk Manag 2022; 18: 603-615
• 54 Shammas NW, Shammas G, Jones-Miller S. JET-RANGER Investigators. Jetstream atherectomy with paclitaxel-coated balloons: 3-year outcomes of the prospective randomized JET-RANGER study. Int J Angiol 2024; 34 (01) 56-59
• 55 Rocha-Singh KJ, Sachar R, DeRubertis BG. et al; REALITY Investigators. Directional atherectomy before paclitaxel coated balloon angioplasty in complex femoropopliteal disease: the VIVA REALITY study. Catheter Cardiovasc Interv 2021; 98 (03) 549-558
• 56 Zeller T, Langhoff R, Rocha-Singh KJ. et al; DEFINITIVE AR Investigators. Directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency: twelve-month results of the DEFINITIVE AR study. Circ Cardiovasc Interv 2017; 10 (09) e004848
• 57 Roberts D, Niazi K, Miller W. et al; DEFINITIVE Ca++ Investigators. Effective endovascular treatment of calcified femoropopliteal disease with directional atherectomy and distal embolic protection: final results of the DEFINITIVE Ca⁺⁺ trial. Catheter Cardiovasc Interv 2014; 84 (02) 236-244
• 58 Tepe G, Brodmann M, Bachinsky W. et al. Intravascular lithotripsy for peripheral artery calcification: mid-term outcomes from the randomized disrupt PAD III trial. J Soc Cardiovasc Angiogr Interv 2022; 1 (04) 100341
• 59 Adams G, Soukas PA, Mehrle A, Bertolet B, Armstrong EJ. Intravascular lithotripsy for treatment of calcified infrapopliteal lesions: results from the disrupt PAD III observational study. J Endovasc Ther 2022; 29 (01) 76-83
• 60 Armstrong EJ, Adams G, Soukas PA. et al. Intravascular lithotripsy for peripheral artery calcification: 30-day outcomes from the disrupt PAD III observational study. J Endovasc Ther 2024;
• 61 Shammas NW, Mangalmurti S, Bernardo NL. et al. Intravascular lithotripsy for treatment of severely calcified common femoral artery disease: results from the disrupt PAD III observational study. J Endovasc Ther 2024;
• 62 Adams G, Shammas N, Mangalmurti S. et al. Intravascular lithotripsy for treatment of calcified lower extremity arterial stenosis: initial analysis of the disrupt PAD III study. J Endovasc Ther 2020; 27 (03) 473-480
• 63 Radaideh Q, Shammas NW, Shammas WJ, Shammas GA. Shockwave lithoplasty in combination with atherectomy in treating severe calcified femoropopliteal and iliac artery disease: a single-center experience. Cardiovasc Revasc Med 2021; 22: 66-70
• 64 Krievins DK, Halena G, Scheinert D. et al. One-year results from the DETOUR I trial of the PQ Bypass DETOUR system for percutaneous femoropopliteal bypass. J Vasc Surg 2020; 72 (05) 1648-1658.e2
• 65 Lyden SP, Soukas PA, De A. et al; DETOUR2 Trial Investigators. DETOUR2 trial outcomes demonstrate clinical utility of percutaneous transmural bypass for the treatment of long segment, complex femoropopliteal disease. J Vasc Surg 2024; 79 (06) 1420-1427.e2
• 66 Final Results of the DETOUR2 Study: Durability of Percutaneous Transmural Arterial Bypass for Treatment of Complex Femoropopliteal Disease. Presented by: Sean P. Lyden, MD at VIVA, Las Vegas, November 2025. Accessed December 21, 2025, at: https://viva-foundation.org/news-article?id=191895
• 67 Shammas NW, Shammas WJ, Jones-Miller S. et al. Optimal vessel sizing and understanding dissections in infrapopliteal interventions: data from the iDissection below the knee study. J Endovasc Ther 2020; 27 (04) 575-580
• 68 Ko Y-G, Lee S-J, Ahn C-M. et al; IVUS-DCB investigators. Intravascular ultrasound-guided drug-coated balloon angioplasty for femoropopliteal artery disease: a clinical trial. Eur Heart J 2024; 45 (31) 2839-2847
• 69 Shin J, Ahn C-M, Lee S-J. et al; IVUS-DCB investigators. Twenty-four-month outcomes of intravascular ultrasound-guided drug-coated balloon angioplasty for femoropopliteal artery disease. J Am Heart Assoc 2025; 14 (16) e041564
• 70 Setogawa N, Ohbe H, Matsui H, Yasunaga H. Amputation after endovascular therapy with and without intravascular ultrasound guidance: a nationwide propensity score-matched study. Circ Cardiovasc Interv 2023; 16 (04) e012451
• 71 Smith JA, Yang L, Chen L. et al. Trends and outcomes associated with intravascular ultrasound use during femoropopliteal revascularization in the Vascular Quality Initiative. J Vasc Surg 2023; 78 (01) 209-216.e1
• 72 Allan RB, Puckridge PJ, Spark JI, Delaney CL. Impact of intravascular ultrasound on femoropopliteal artery endovascular interventions: a randomized controlled trial. JACC Cardiovasc Interv 2022; 15 (05) 536-546
• 73 Divakaran S, Parikh SA, Hawkins BM. et al. Temporal trends, practice variation, and associated outcomes with intravascular ultrasound use during peripheral arterial intervention. JACC Cardiovasc Interv 2022; 15 (20) 2080-2090
• 74 Secemsky EA, Mosarla RC, Rosenfield K. et al. Appropriate use of intravascular ultrasound during arterial and venous lower extremity interventions. JACC Cardiovasc Interv 2022; 15 (15) 1558-1568
• 75 Secemsky EA, Aronow HD, Kwolek CJ. et al. Intravascular ultrasound use in peripheral arterial and deep venous interventions: multidisciplinary expert opinion from SCAI, AVF, AVLS, SIR, SVM, and SVS. J Vasc Interv Radiol 2024; 35 (03) 335-348
• 76 Mukherjee D, White CJ. Role of IVUS imaging during arterial and venous lower extremity interventions: hype or meaningful benefits?. JACC Cardiovasc Interv 2022; 15 (15) 1579-1581
• 77 Ouriel K, Veith FJ, Sasahara AA. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med 1998; 338 (16) 1105-1111
• 78 Ouriel K, Shortell CK, DeWeese JA. et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg 1994; 19 (06) 1021-1030
• 79 Veenstra EBJ, van der Laan MJ, Zeebregts CJ, de Heide EJ, Kater M, Bokkers RPH. A systematic review and meta-analysis of endovascular and surgical revascularization techniques in acute limb ischemia. J Vasc Surg 2020; 71 (02) 654-668.e3
• 80 Ciofani L, Zenunaj G, Ricci R, Cosacco AM, Baldazzi G, Fargion AT. Pharmacomechanical thrombectomy versus catheter-directed thrombolysis in acute limb ischemia: a systematic review and meta-analysis. J Cardiovasc Surg (Torino) 2025;
• 81 Allie DE, Hebert CJ, Lirtzman MD. et al. Novel simultaneous combination chemical thrombolysis/rheolytic thrombectomy therapy for acute critical limb ischemia: the power-pulse spray technique. Catheter Cardiovasc Interv 2004; 63 (04) 512-522
• 82 Schernthaner MB, Samuels S, Biegler P, Benenati JF, Uthoff H. Ultrasound-accelerated versus standard catheter-directed thrombolysis in 102 patients with acute and subacute limb ischemia. J Vasc Interv Radiol 2014; 25 (08) 1149-1156 , quiz 1157
• 83 Auda ME, Ratner M, Pezold M. et al. Short-term outcomes of endovascular management of acute limb ischemia using aspiration mechanical thrombectomy. Vascular 2025; 33 (01) 34-41
• 84 Maldonado TS, Powell A, Wendorff H. et al; STRIDE study group. Safety and efficacy of mechanical aspiration thrombectomy for patients with acute lower extremity ischemia. J Vasc Surg 2024; 79 (03) 584-592.e5
• 85 Maldonado TS, Powell A, Wendorff H. et al; STRIDE study group. STRIDE study post hoc analysis shows first-line mechanical aspiration thrombectomy for either in-stent or in-graft versus native vessel thrombosis in lower extremity acute limb ischemia yields similar outcomes. J Vasc Surg 2025;
• 86 Mukherjee D. Optimal management of femoropopliteal arterial disease in patients with intermittent claudication. JACC Cardiovasc Interv 2023; 16 (13) 1679-1681